Compare GKOS & TMHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | TMHC |
|---|---|---|
| Founded | 1998 | 1936 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.2B |
| IPO Year | 2015 | 2013 |
| Metric | GKOS | TMHC |
|---|---|---|
| Price | $107.89 | $64.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $122.08 | $76.83 |
| AVG Volume (30 Days) | ★ 1.1M | 881.3K |
| Earning Date | 10-29-2025 | 10-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.21 |
| EPS | N/A | ★ 8.31 |
| Revenue | $469,820,000.00 | ★ $8,378,329,000.00 |
| Revenue This Year | $30.89 | N/A |
| Revenue Next Year | $24.36 | N/A |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | ★ 30.38 | 6.98 |
| 52 Week Low | $73.16 | $51.90 |
| 52 Week High | $163.71 | $74.09 |
| Indicator | GKOS | TMHC |
|---|---|---|
| Relative Strength Index (RSI) | 73.56 | 64.08 |
| Support Level | $104.11 | $61.79 |
| Resistance Level | $107.18 | $63.98 |
| Average True Range (ATR) | 4.40 | 1.75 |
| MACD | 1.26 | 0.70 |
| Stochastic Oscillator | 92.97 | 94.37 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.